Meeting Objectives:
-
- Optimize cholesterol control in patients with ASCVD at very high-risk for future events by bridging guideline-practice gaps, advocating adjunctive therapies when statins alone are insufficient for LDL targets, and aligning patient-centric care with recommendations.
- Examine efficacy, safety, and costs/value for injectable LDL-C–lowering therapies beyond statins to inform clinical practice and referral decisions for patients with ASCVD at very high-risk for secondary cardiovascular events.
- Discuss the pharmacist’s role in treatment algorithms and creating shared decision-making tools to appropriately intensify cholesterol management in patients with prior ASCVD events who remain at very high-risk despite standard statin therapy.
Share This Event